Sjögren’s Syndrome New Drug Pipeline Grows but Not Fast Enough for Patients

Sjögren’s syndrome patients had bad news this past summer when medical professionals learned at the EULAR Annual Congress in Madrid that Bristol-Myers Squibb reported its abatacept, considered a lead investigational treatment candidate, failed during a Phase III trial. There is no drug approved by the FDA for primary Sjögren’s syndrome.
Clinical Updates
Recently Steven E. Carsons, chief of rheumatology division at NYU Winthrop Hospital, and a senior associate dean for translational medicine at NYU Long Island School of Medicine, noted in a Healio article that this is partially due to the wide spectrum of clinical involvements related to the disease.
Pipeline Grows
Just a handful of years ago, there was little pipeline. That has changed, reports Judith James, MD, PhD Professor and chair of the arthritis and clinical immunology research program at the Oklahoma Medical Research Foundation.
In fact, Healio reports more than 40 ongoing clinical trials focusing on the disease including:

Filgotinib plus lanraplenib plus triabrutinib (Galapagos/Gilead/Onco)
Benlysta (belimumab, GSK)
Ianalumab and iscalimab (Novartis)
Tibulizumab (Lilly)

Lead Research/Investigator
Steven E. Carso...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee